C4 Therapeutics

$30.71
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$1.95 (-5.97%) Today
$0.00 (0.00%) As of 12:00 AM UTC after-hours

Why Robinhood?

You can buy or sell CCCC and other stocks, options, and ETFs commission-free!

About CCCC

C4 Therapeutics, Inc. provides new class of targeted protein degradation. It develops Degronimid platform that incorporates small molecule binders to target disease-causing proteins and facilitate their destruction and clearance from the cell through the natural ubiquitin and proteasome system.

CEO
Andrew J. Hirsch
Employees
99
Headquarters
Watertown, Massachusetts
Founded
2015
Market Cap
1.47B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
525.79K
High Today
$32.99
Low Today
$30.33
Open Price
$32.60
Volume
513.27K
52 Week High
$48.98
52 Week Low
$22.40

CCCC Earnings

-$17.55
-$11.70
-$5.85
$0.00
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected May 13, After Hours

You May Also Like

AAA
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure